Dietary supplementation with methyl donors reduces fatty liver and modifies the Fatty Acid Synthase DNA methylation profile in rats fed an obesogenic diet

Published in Genes & Nutrition. 2012

Cordero P, Gomez-Uriz AM, Campion J, Milagro FI, Martinez JA
Department of Nutrition and Food Sciences, Physiology and Toxicology
University of Navarra, c/ Irunlarrea 1, 31008. Pamplona, Spain

CORRESPONDING AUTHOR
Prof. J. Alfredo Martínez
Department of Nutrition, Food Science, Physiology and Toxicology
University of Navarra
C/Irunlarrea s/n
31008 Pamplona, SPAIN
Phone: 0034 948 425600
Fax: 0034 948 425649
E-mail address: jalfmtz@unav.es
ABSTRACT

Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the first hepatic manifestations of metabolic syndrome, whose progression can lead to cirrhosis and hepatic carcinoma. Interestingly, methyl donor supplementation could improve obesogenic diet-induced hepatic triglyceride accumulation.

The aim of this research is to describe methyl donor effects on a high-fat-sucrose (HFS) diet in both sexes and epigenetic changes induced on Fatty Acid Synthase (FASN) promoter methylation pattern as well as gene expression of NAFLD key metabolic genes.

24 male and 28 female Wistar rats were assigned to three dietary groups: control, HFS and HFS supplemented with methyl donors (choline, betaine, vitamin B₁₂ and folic acid). After eight weeks of treatment, somatic, biochemical, mRNA and epigenetic measurements were performed.

Rats fed the HFS diet presented an overweight phenotype and alterations in plasma biochemical measurements. Methyl donor supplementation reverted the HFS-diet-induced hepatic triglyceride accumulation. Analysis of FASN promoter cytosine methylation showed changes in both sexes due to the obesogenic diet at -1096, -780, -778 and -774 CpG sites with respect to the transcriptional start site. Methyl donor supplementation modified DNA methylation at -852, -833, -829, -743 and -733 CpGs depending on the sex. RT-PCR analysis confirmed that FASN expression tended to be altered in males.

Our findings reinforce the hypothesis that methyl donor supplementation can prevent hepatic triglyceride accumulation induced by obesogenic diets in both sexes. Changes in liver gene expression profile and epigenetic-mediated mechanisms related with FASN DNA hypermethylation could be involved in methyl donor-induced NAFLD improvement.

KEY WORDS: Obesity, NAFLD, DNA methylation, high fat sucrose diet

INTRODUCTION
Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by a triglyceride accumulation in hepatocytes that can affect their normal function (Angulo 2002). NAFLD prevalence is rising in parallel with the obesity pandemic being related to cardiovascular risk (Chen et al. 2010; Edens et al. 2009) and insulin resistance (Koot et al. 2011). This disease (NAFLD) is considered the primary hepatic manifestation of metabolic syndrome, being the cause of several metabolic disorders (Fu et al. 2011). Furthermore, the increase of liver triglyceride depots can progress to Non-Alcoholic Steatohepatitis (NASH) and later, to cirrhosis, that represents an irreversible stage that may end in hepatic carcinoma, liver transplantation or a hepatic-related complication death (Ekstedt et al. 2006).

Besides genetic make-up, unhealthy lifestyles including physical inactivity and obesogenic diets are involved in early onset of fat accumulation in the liver (Carmiel-Haggai et al. 2005; Gaemers et al. 2011; Moore et al. 2010). At this stage, adipokines such as visfatin or proinflammatory cytokines like TNF alpha, IL-6 or IL-10 (Dinant et al. 2007; Jarrar et al. 2008) as well as enzymes such as Fatty Acid Synthase (FASN), one of the key metabolic genes for de novo lipogenesis, may play a role in the pathogenesis of NAFLD. In this pathway acetyl CoA carboxylase alpha (ACACA) catalyzes the conversion of acetyl CoA to malonyl CoA and FASN catalyzes the conversion of this molecule into long chain saturated fatty acids (Strable et al. 2010). Both enzymes are directly regulated by sterol regulatory elements binding protein (SREBP), which is a regulatory transcription factor (Eberle et al. 2004; Kohjima et al. 2007). Other possible mediators in liver steatosis evolution are fatty acid binding proteins (FABP), which have roles including fatty acid uptake, transport and metabolism, lipases, such as monoglyceride lipase (MGLL) that hydrolyzes triglycerides to fatty acids and glycerol, or chemokine ligand 2 (CCl2), a cytokine involved in the inflammatory response and atherosclerosis (Bastarrachea RA et al. 2007).

The research of dietary models of NAFLD and development stages in animal models include the assessment of changes by methyl donor group administration on the diet, with depletion of choline and methionine (Rinella et al. 2008; Vetelainen et al. 2007), or of vitamin B12 and folic acid (Brunaud et al. 2003). These impairments alter the hepatic epigenetic profile and accelerate
the progression from slight liver injury to cancer (Pogribny et al. 2009; Starlard-Davenport et al. 2010). On the contrary, a promethylation cocktail including choline, betaine, folic acid and vitamin B₁₂ in a transgenerational model of obesity in agouti mice produced phenotypical and epigenetic alterations, where the agouti transposon was blocked and heritable obesity minimized (Waterland et al. 2008).

Previous published studies have tested methyl donor dietary supplementation in a model of obesity and NAFLD in male adults Wistar rats and have demonstrated an improvement in liver fat accumulation (Cordero et al. 2011b). The objective of this research is to describe the effects of methyl donor supplementation following an obesogenic diet in both sexes with special focus on the possible epigenetic changes induced in the methylation pattern of FASN promoter as well as gene expression of key metabolic genes in de novo lipogenesis and related to lipid metabolism in the liver.

MATERIAL AND METHODS

Animals, diets and experimental design

A total of 24 male and 28 female twelve-week-old Wistar rats (initial body weight 238 ± 5 and 177 ± 2 g respectively ) supplied by the Applied Pharmacobiology Center (CIFA, Pamplona, Spain), were housed at 21–23 °C with a 12 h light cycle (8 am – 8 pm) and assigned to three different dietary groups; control (C, n= 7 males and 9 females), high- fat-sucrose (HFS, n= 9 males and 9 females) and high-fat-sucrose supplemented group (HFSsupp, n= 8 males and 10 females) as previously described (Cordero et al. 2011b). The Control group was fed a standard chow diet (2014 Teklad Global 14% Protein Rodent Maintenance Diet, Harlan Iberica, Barcelona, Spain) containing 20% of the energy as protein, 67% as carbohydrate and 13% as lipid in dry weight, whereas HFS groups were fed an obesogenic diet (D12451, Research Diets, New Brunswick, NJ, USA) containing 20% of the energy as protein, 35% as total carbohydrates (17% sucrose) and 45% as fats in dry weight. Finally, a methyl donor supplementation cocktail that contained betaine (5 g/kg diet, Sigma-Aldrich, Missouri, USA),
choline (5.37 g/kg diet, Sigma-Aldrich, Missouri, USA), folic acid (5.5 mg/kg diet, Sigma-Aldrich, Missouri, USA) and vitamin B\textsubscript{12} (0.5 mg/kg diet, Sigma-Aldrich, Missouri, USA) was mixed with HFS powderized pellets to obtain the HFS methyl supplemented diet. In order to maintain the same diet consistency, chow and HFS pellets were also powderized for the other two dietary groups. After 8 weeks of ad libitum dietary treatment, the animals were euthanized, blood was collected and plasma stored at -20 °C, while samples of liver, adipose depots (subcutaneous, retroperitoneal, perigonadal and mesenteric) and gastrocnemius muscle were carefully dissected, weighed and stored immediately at -80 °C. All the procedures performed agreed with the National and Institutional Guidelines of the Animal Care and Use Committee at the University of Navarra.

**Serum measurements**

Plasma glucose (HK-CP kit; ABX diagnostic, Montpellier, France), HDL-cholesterol (HDL direct CP; ABX diagnostic, Montpellier, France), lactate (L-Lactate; Randox Laboratories Ltd., Crumlin, UK), triglycerides (Triglycerides; Randox Laboratories Ltd., Crumlin, UK) and homocysteine (Homocysteine Enzymatic Assay; Demeditec Diagnostics, Kiel, Germany) levels were measured using automated COBAS MIRA equipment (Roche, Basel, Switzerland). Plasma insulin levels were determined by ELISA (Mercodia AB, Uppsala, Sweden) in automated TRITURUS equipment (Grifols International S.A., Barcelona, Spain).

**Hepatic triglyceride content**

Liver samples were homogenized with a Branson Sonifier 250 (Branson Ultrasonic Corporation, Danbury, USA) and triglyceride content was measured with a commercial reagent kit (ABX Pentra, Montpellier, France) adapted for the COBAS MIRA equipment (Roche, Basel, Switzerland).

**Determination of FASN promoter methylation status**

The quantitative analysis of DNA methylation in the promoter region of FASN was performed using an Sequenom EpiTyper approach (Sequenom, CA, USA), which relies on base-specific cleavage followed by MALDI-TOF mass
spectrometry (Milagro et al. 2011). Briefly, genomic DNA was extracted from liver samples by using the QIAamp DNA Mini Kit (Qiagen Gmbh, Hilden, Germany) and 500 ng were modified by using Epitec Bisulfite Kit (Qiagen Gmbh, Hilden, Germany). Primers designed for quantitative analysis of the degree of FASN promoter methylation levels were aggaagagagAAGTAAGGTTTTGAGGTTTTGGTTT for forward (5′→3′) and cagtaatatcactatagggagaaggctCTCAAACACCACCCTTTCTATAAC for reverse primers (5′→3′), amplifying from -1,177 to -688 with respect to the transcriptional start site. PCR products were excised from agarose gels, purified, treated with shrimp alkaline phosphatase to dephosphorylate unincorporated dNTPs and later processed by MassArray Matrix Liquid Handler. Samples were heat-inactivated and subsequently incubated with Transcleave mix for concurrent in vitro transcription and base-specific cleavage. After deionization with Sequenom resin, samples were transferred to the spectroCHIP array by nanodispensation. Analysis with the Sequenom MALDI-TOF MS Compact Unit was performed following a 4-point calibration with oligonucleotides of different mass provided in the Sequenom kit. Matched peak data was exported using EpiTyper software and analyzed (CpGs shown in figure 2).

**Real time PCR**

Total RNA was isolated from the liver according to Trizol manufacturer’s instructions (Invitrogen, CA, USA) and purified with the RNeasy kit (Qiagen, MD, USA). cDNA was synthesized using RT2 Standard Kit as described by suppliers (Qiagen, MD, USA). Next, quantitative real-time PCR was performed using ABI PRISM 7900 HT Fast Real-Time PCR system (Applied Biosystems, TX, USA) with RT2 qPCR commercial primers (Qiagen, MD, USA): SREBP1 (XM_213329), ACACA (NM_022193), FASN (NM_017332), MGLL (NM_138502), CCL2 (NM_031530) and FABP4 (NM_053365). Fold change between groups was calculated using the $2^{-\Delta\Delta C_t}$ method. The gene expression levels were normalized with β-actin (ACTB, NM_031144), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, NM_017008) and cyclophilin A (PPIA, NM_017101) as internal controls and using Genorm Software.
Statistical analysis

All results are expressed as means ± standard error (SE). Data was evaluated separately by sex using one-way ANOVA followed by a DMS post-hoc test for multiple comparisons (C, HFS, HFSsupp). The level of probability was set at p<0.05 as statistically significant. All analyses were performed using SPSS 15.0 package for Windows (Chicago, IL, USA).

RESULTS

As expected, HFS induced an obese phenotype in both sexes (tables 1 and 2), although no relevant differences were found between the rats fed the HFS and HFSsupp diets regarding body weight gain, adiposity or muscle and liver weights. However, there was an increase in liver fat accumulation due to HFS diet in both sexes (96%, p<0.01 in males and 29%, p<0.05 in females) (Figure 1). Interestingly, the methyl donor supplementation improved this adverse dietary effect and decreased the liver triglyceride content in both males (30%, p<0.05) and in females (39%, p<0.01).

In this trial, the HFS diet induced a disruption of glucose homeostasis in male (Table 1) rats but not in females (Table 2). Plasma glucose (17%, p<0.05) and insulin levels (112%, p<0.001) were increased in males by the obesogenic diet but not in females, whereas plasma lactate levels were also higher in males fed a HFS diet (28%, p<0.05) with a reversion due to the methyl supplementation (-33%, p<0.05). In females a HFS-diet decreased cHDL levels (-29%, p<0.05), which was reverted by the methyl donor supplementation (34%, p<0.05).

The analysis of the DNA methylation patterns of the FASN promoter in males (Figure 2A) showed a significant hypomethylated status (p<0.001) at CpG1 in the HFS and HFSsupp groups when compared to the control group. Interestingly, CpG10-11 was hypermethylated (164%, p<0.01) in the HFSsupp as compared to control group, while the HFS group showed an intermediate
value with no statistical differences with either of the other two groups. The obesogenic diet also decreased the methylation levels of

Table 1. Weight-related and plasma measurements of male Wistar rats after eight weeks of dietary treatments.

<table>
<thead>
<tr>
<th>Weight-related measurements</th>
<th>Male Dietary Groups</th>
<th>Male Dietary Groups</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C(n=7)</td>
<td>HFS(n=9)</td>
<td>HFSsupp (n=8)</td>
</tr>
<tr>
<td><strong>Weight-related measurements</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight gain (g)</td>
<td>152.6 ± 7.3 a</td>
<td>191.8 ± 13.0 b</td>
<td>196.8 ± 14.0 b</td>
</tr>
<tr>
<td>Subcutaneous WAT (%)</td>
<td>1.89 ± 0.09 a</td>
<td>3.14 ± 0.19 b</td>
<td>3.10 ± 0.13 b</td>
</tr>
<tr>
<td>Retroperitoneal WAT (%)</td>
<td>2.63 ± 0.25 a</td>
<td>3.65 ± 0.16 b</td>
<td>3.72 ± 0.21 b</td>
</tr>
<tr>
<td>Epididymal WAT (%)</td>
<td>2.32 ± 0.20 a</td>
<td>3.10 ± 0.11 b</td>
<td>3.32 ± 0.20 b</td>
</tr>
<tr>
<td>Mesenteric WAT (%)</td>
<td>1.06 ± 0.11 a</td>
<td>1.45 ± 0.09 b</td>
<td>1.45 ± 0.13 b</td>
</tr>
<tr>
<td>Liver (%)</td>
<td>2.32 ± 0.03 a</td>
<td>2.37 ± 0.06 a</td>
<td>2.25 ± 0.06 a</td>
</tr>
<tr>
<td>Gastrocnemius muscle (%)</td>
<td>0.54 ± 0.02 a</td>
<td>0.51 ± 0.01 a</td>
<td>0.51 ± 0.01 a</td>
</tr>
<tr>
<td><strong>Plasma values</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>114.5 ± 5.3 a</td>
<td>134.0 ± 4.7 b</td>
<td>122.9 ± 5.4 a,b</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>69.2 ± 3.8 a</td>
<td>72.0 ± 2.8 a</td>
<td>79.6 ± 3.0 a</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>108.4 ± 6.8 a</td>
<td>100.0 ± 11.3 a</td>
<td>103.1 ± 9.6 a</td>
</tr>
<tr>
<td>Lactate (mg/dL)</td>
<td>25.6 ± 3.2 a,b</td>
<td>32.6 ± 3.2 a</td>
<td>22.1 ± 1.1 b</td>
</tr>
<tr>
<td>Homocysteine (µmol/L)</td>
<td>17.9 ± 1.0 a</td>
<td>18.7 ± 3.1 a</td>
<td>14.3 ± 1.0 a</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>20.3 ± 2.4 a</td>
<td>43.1 ± 5.0 b</td>
<td>46.7 ± 3.6 b</td>
</tr>
</tbody>
</table>

All the results are expressed as the mean ± SE. Statistical analyses were performed using one way Anova and Tukey post-hoc test. Different letters (a, b) indicate significant differences between groups of at least p < 0.05. (WAT; white adipose tissue, C; control group, HFS; high-fat-sucrose group, HFSsupp; high-fat-sucrose supplemented with methyl donors group, * p < 0.05, ** p < 0.01, *** p < 0.001).

Table 2. Weight-related and plasma measurements of female Wistar rats after eight weeks of dietary treatments.

<table>
<thead>
<tr>
<th>Weight-related measurements</th>
<th>Female Dietary Groups</th>
<th>Female Dietary Groups</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C(n=9)</td>
<td>HFS(n=9)</td>
<td>HFSsupp (n=10)</td>
</tr>
<tr>
<td><strong>Weight-related measurements</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight gain (g)</td>
<td>68.7 ± 5.9 a</td>
<td>102.8 ± 8.9 b</td>
<td>109.4 ± 11.4 b</td>
</tr>
<tr>
<td>Subcutaneous WAT (%)</td>
<td>1.40 ± 0.14 a</td>
<td>2.02 ± 0.26 a,b</td>
<td>2.27 ± 0.28 b</td>
</tr>
<tr>
<td>Retroperitoneal WAT (%)</td>
<td>1.87 ± 0.19 a</td>
<td>2.70 ± 0.29 b</td>
<td>3.09 ± 0.24 b</td>
</tr>
<tr>
<td>Periovaric WAT (%)</td>
<td>2.42 ± 0.30 a</td>
<td>3.53 ± 0.49 a</td>
<td>3.84 ± 0.41 a</td>
</tr>
<tr>
<td>Mesenteric WAT (%)</td>
<td>1.28 ± 0.18 a</td>
<td>1.63 ± 0.19 a</td>
<td>1.62 ± 0.21 a</td>
</tr>
<tr>
<td>Liver (%)</td>
<td>2.18 ± 0.03 a</td>
<td>2.14 ± 0.06 a</td>
<td>2.24 ± 0.07 a</td>
</tr>
<tr>
<td>Gastrocnemius muscle (%)</td>
<td>0.59 ± 0.02 a</td>
<td>0.55 ± 0.03 a</td>
<td>0.51 ± 0.04 a</td>
</tr>
<tr>
<td><strong>Plasma values</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>103.4 ± 6.1 a</td>
<td>108.9 ± 3.7 a</td>
<td>119.3 ± 6.7 a</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>56.8 ± 4.3 a</td>
<td>40.4 ± 4.6 b</td>
<td>54.2 ± 4.5 a</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>86.5 ± 6.9 a</td>
<td>57.7 ± 5.3 a</td>
<td>74.1 ± 13.2 a</td>
</tr>
<tr>
<td>Lactate (mg/dL)</td>
<td>27.8 ± 4.3 a</td>
<td>26.1 ± 3.4 a</td>
<td>34.3 ± 4.7 a</td>
</tr>
<tr>
<td>Homocysteine (µmol/L)</td>
<td>15.6 ± 1.1 a</td>
<td>15.2 ± 0.8 a</td>
<td>14.1 ± 0.9 a</td>
</tr>
<tr>
<td>Insulin (µU/mL)</td>
<td>15.5 ± 4.7 a</td>
<td>16.4 ± 3.3 a</td>
<td>21.2 ± 4.5 a</td>
</tr>
</tbody>
</table>

All the results are expressed as the mean ± SE. Statistical analyses were performed using one way Anova and Tukey post-hoc test. Different letters (a, b) indicate significant differences
between groups of at least $p < 0.05$. (WAT; white adipose tissue, C; control group, HFS; high-fat-sucrose group, HFSsupp; high-fat-sucrose supplemented with methyl donors group, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).

Figure 1. Hepatic triglyceride content (in µmol of triglycerides per gram of tissue) in (A) male and (B) female Wistar rats. Different letters indicate significant differences between groups of at least $p < 0.05$ (C; control group - white, HFS; high-fat-sucrose group - grey, HFSsupp; high-fat-sucrose supplemented with methyl donors group - black).

CpG17-18-19 (-50%, $p<0.001$ HFS and -47%, $p<0.001$ HFSsupp) in males. In females (Figure 2B), CpG1 was hypomethylated by the obesogenic diet ($p<0.001$), as opposed to the area covered by CpG9 and CpG10-11 which showed significant changes due to the HFS diet (133%, $p<0.05$ and 104%, $p<0.001$) and the methyl donor supplementation increased this dietary effect (71%, $p<0.05$ and 34%, $p<0.001$), showing an additional effect between diet and methyl donor supplementation. CpG17-18-19 methylation profile was also similar to that presented in males, with a hypomethylation due to the obesogenic diet (-40%, $p<0.01$ HFS and -44%, $p<0.01$ HFSsupp). There was also a hypermethylation of CpG20-21 induced by the methyl donor supplementation when compared to both C and HFS diets (767%, $p<0.001$), which showed a lower methylation percentage than the control group (-72%, $p<0.01$). Finally, in females, promoter methylation mean values did not change due to diet, but presented a significative increase (40%, $p<0.05$) when comparing HFS with HFS supplemented diet.
Additionally, the hepatic expression of some key genes involved in lipid metabolism-related genes was analyzed by RT-PCR in male Wistar rats (figure 3). Regarding de novo lipogenesis pathway, significant changes were found in ACACA expression (p<0.01), which was 66% higher due to methyl donor supplementation. Whereas, SREBP1 and

![DNA Methylation Analysis](image)

**Figure 2.** Quantitative DNA methylation analysis using MassARRAY system for FASN promoter in liver tissue from (A) male and (B) female Wistar rats (TSS; transcriptional start site). The results are shown as percentages of methylation. All results are expressed as mean ± SD. Different letters indicate significant differences between groups of at least p < 0.05 (Control group, white; high-fat-sucrose group, grey; high-fat-sucrose supplemented with methyl donors group; black; ** p < 0.01, *** p < 0.001).

FASN only showed a trend to increase (p=0.095 and p=0.082). The cytokine CCL2 was markedly downregulated (-76%, p<0.05) by methyl supplementation.
when compared to controls, with no significant changes induced by HFS diet. The lypolitic enzyme MGLL showed a decrease in the mRNA expression levels in rats fed the obesogenic diet (-30%, $p<0.05$). Finally, FABP4 did not show significant differences ($p=0.093$) between the experimental dietary groups.

Figure 3. Expression levels (mRNA) of SREBP1, CACA, FASN, MGLL, CCL2 and FABP4 measured by RT-PCR in liver from C, HFS and HFSsupp groups in male Wistar rats. Data are presented as mean ± SE measured in arbitrary units after normalization with ACTB, GAPDH and PPIA. Different letters in the same gene indicate statistically significant differences between groups of at least $p < 0.05$. (control group, white; high-fat-sucrose group, grey; high-fat-sucrose supplemented with methyl donors group, black; * $p < 0.05$, ** $p < 0.01$).

**DISCUSSION**

NAFLD is the main early liver manifestation of the metabolic syndrome, and has a close association with obesity (Moore et al. 2010). The increased fat depots tend to expand to the visceral organs affecting their functionality (Guri et al. 2011). In this way, this research has been designed to be focused on the initial stage of liver damage, NAFLD, since it could potentially be easier to treat or revert than more advanced stages such as NASH or cirrhosis. For that reason, it was decided to supplement HFS diet for a period of eight weeks, when obese phenotype was at the beginning (Cordero et al. 2011b; Milagro et al. 2006). We analyzed all variables according to the sex, as gender is a factor that appears to confer differential vulnerability to obesogenic diets (Clark et al. 2011), since many of the relevant studies in this field have been conducted only in males. In
this way, previous investigations have described that obesity-linked disorders such as insulin and glucose homeostasis or fat depot distributions differ between sexes (Priego et al. 2008). It is also known that steroid hormones can play a role in metabolism, accumulation and distribution of the different adipose depots (Mayes et al. 2004). Thus, we decided to analyze in a separate way males and females and also, to avoid possible disturbances and errors derived from hormonal status, we determined gene expression only in male rats.

Biochemical variables were affected by an obesogenic diet and methyl donor supplementation. In males, the increase in insulin levels due to HFS diet (Boque et al. 2009) was not enough to control glucose circulating levels. Methyl donor supplemented groups presented an intermediate value that suggests a partial protection of these methyl substrates on glucose homeostasis. In this sense, previous studies during the perinatal nutrition period have shown that maternal folic acid supplementation decreases glucose levels in the offspring (Chmurzynska et al. 2011), while its depletion, together with low choline levels, leads to increased plasma glucose levels (Maloney et al. 2009). However, other studies have reported that hepatic steatosis could be associated to increased lactate levels (Kalhan et al. 2011). Lactate can be used as a substrate activating liver gluconeogenesis, which may contribute to increase glucose levels. However, HDL cholesterol, an atherogenic protective factor, is decreased in animals fed obesogenic and sucrose enriched diets (Kamgang et al. 2005) being known that this molecule removes cholesterol from the peripheral tissues transporting it to the liver to be metabolized (Tall 2008). Interestingly, in this study a methyl donor cocktail can present a beneficial cardiovascular effect in female Wistar rats by increasing cHDL plasma levels during an obesogenic-proatherogenic dietary treatment.

The dietary depletion of some micronutrients such as choline or betaine has been repeatedly used to generate models of hepatic cirrhosis (Pogribny et al. 2009; Tryndyak et al. 2011; Vetelainen et al. 2007) and betaine supplementation has been studied as a potential hepatoprotective substrate (Kathirvel 2010). Folic acid and vitamin B₁₂ have mainly been studied in periconceptual periods to prevent neural tube defects and future congenital diseases (Ba et al. 2011; Chmurzynska et al. 2011; Dhobale et al. 2011; Wilson
et al. 2007). The effects of these two promethylating vitamins are related with epigenetic changes in the offspring due to the accessibility of the DNA during early development (Ozanne et al. 2007). The supplementation cocktail we used, was tested in agouti mice and it was found that the agouti transposon was blocked by epigenetic silencing, whereas transgenerational heredability of obesity and skin colour was interrupted (Waterland et al. 2008). A previous investigation of our group (Cordero et al. 2011b) reported that the diet supplementation of promethylling agents during adulthood had a positive impact effect on hepatic triglyceride accumulation. According to the biochemical onset of this disease, different studies have reported that changes in epigenetic marks could be related to liver damage. For example, insulin resistance levels in patient with NAFLD showed a relation with PPARgamma hepatic methylation levels (Sookoian et al. 2010) and maternal hypoproteicnic diet is related to changes in Igf2 methylation levels in the offspring (Gong et al. 2010). On the other hand, obesogenic diets also have the potential to modify the epigenome (Campion et al. 2009), mainly during perinatal periods (Martinez et al. 2012; Vucetic et al. 2010), but also in adulthood (Lomba et al. 2010). On the contrary, the epigenetic pattern may also act as a response element for dietary treatments (Cordero et al. 2011a; Milagro et al. 2011). In this context, changes in FASN methylation in epididimal adipose tissue induced by the intake of an obesogenic diet have been reported in Wistar rats (Lomba et al. 2010). Our results concerning this key enzyme of de novo lipogenesis evidenced changes in its methylation pattern induced by an obesogenic diet, but also by the methyl donor supplementation.

On the other hand, in NAFLD stage the liver increases the uptake and synthesis of fat (Angulo P 2002). Thus, obese rats overexpress genes involved in de novo lipogenesis, including SREBP1, ACACA and FASN. SREBP1 is an activator of many enzymes from this pathway and also for ACACA and FASN (Kohjima et al. 2007). In this research we found a correlation (Electronic Supplementary Material, figure 4) between SREBP1 expression and ACACA (p<0.05, r=0.477) and also with FASN (p<0.05, r=0.463). These outcomes concluded that lipid synthesis in the liver is increased by the obesogenic diet and also by methyl donor supplementation. On the other hand, MGLL lipase is involved in
the activation of intracellular triglyceride hydrolysis to fatty acids and glycerol. In our study, MGLL expression profile showed a decrease attributable to HFS effect. The impact on lipogenic and lipolytic pathways suggests that methyl donor supplementation of a HFS diet increases the total amount of triglycerides produced by the liver decreasing their accumulation, so the explanation could be described in a lipid storage-mobilization and lipolysis more than on synthesis. However, liver FFA uptake is also increased in metabolic syndrome and obesity, in such a way that this situation affects their accumulation in the liver. The analysis of FABP4 expression levels, a protein implicated in fatty acid uptake and upregulated in metabolic syndrome and obesity (Terra et al. 2011), revealed no statistical differences. This FABP isoform is highly expressed in adipose tissue but it has been also associated in liver with fat accumulation in this organ (Westerbacka et al. 2007). Curiously in our study the obesogenic diet induced a trend to increase FABP4 gene expression (p=0.093) that was reverted by methyl donor supplementation. Finally, although we described differences in NAFLD gene expression profile, the pathways that unravel the decrease showed in hepatic triglycerides content are still uncertain being necessary other studies to deepen into these mechanisms.

Contrary as expected, methylation levels in FASN promoter did not correlate with its gene expression levels. It should be kept in mind that the expression of this gene is not only regulated by DNA methylation; there are other epigenetic mechanisms such as histone modifications or microRNA regulation that could affect mRNA levels (Campion et al. 2009).

It appears that methyl donors do not influence fat accumulation in adipose tissue but it seems that methyl donors affect only the fat accumulation in liver (Perseghin 2011). The treatment with methyl donors may not be effective against obesity itself, but this dietary supplementation could decrease the prevalence of NAFLD as the main hepatic manifestation of metabolic syndrome, with all the comorbidities associated to this disease including insulin resistance. In this way, even if this work could be an useful tool in the treatment of NAFLD there are some limitations that researchers have to evaluate in a cautious and appropriate manner, such as the number of individuals, the measurement of
gene expression only in males or the possibility to include other technique in order to validate Sequenom results.

Summing up, supplementation with methyl donor groups in obesogenic diets reverted NAFLD development and associated features in both sexes. One possible mechanism involved in this alteration is by affecting the epigenetic machinery and by inducing DNA hypermethylation or hypomethylation. Indeed, changes in DNA methylation patterns on the FASN gene promoter were associated with the obesogenic diet intake and also with the dietary supplementation with methyl donors.

ACKNOWLEDGEMENTS

The technical assistance of V. Fernandez is gratefully acknowledged as well as Alexandra Claire Simpson for checking the manuscript spelling and grammar for English. “Linea Especial (LE/97)” from University of Navarra for financial support. P. Cordero and A.M. Gomez-Uriz were recipients of predoctoral fellowships from “Asociacion de Amigos de la Universidad de Navarra”. Also RETICS and CIBERobn schemes from Carlos III Institute are gratefully acknowledged.

CONFLICT OF INTEREST STATEMENT

The authors declare no conflict of interest.

ETHICAL STANDARDS

All animal manipulations were made in accordance with European Community Guidelines and University of Navarra Ethical Committee for the use of laboratory animals.
BIBLIOGRAPHY


